創業者・代表取締役

東京大学大学院工学系研究科修了(工学博士)、ウェールズ大学MBAプログラム修了(経営修士)
1999年第一三共株式会社(旧三共株式会社)入社。研究統括部にてバイオロジクス、細胞治療薬の研究、開発に従事。
得意分野は抗体エンジニアリング、物性解析、オープンイノベーション。

取締役　最高技術責任者

名古屋大学大学院理学系研究科修了(理学修士。2025年医学博士取得予定)
2007年協和キリン入社、2015年株式会社ジャパン・ティッシュエンジニアリング(J-TEC)入社。
2020年第一三共株式会社入社。研究統括部にて細胞治療薬の研究に従事。得意分野は血液・腫瘍免疫学、再生医療等製品の品質評価、プロセス開発。

取締役　最高戦略責任者・知財担当

東京大学大学院理学系研究科修了(理学博士)、グロービズ経営大学院修了(経営修士)
2002年第一三共株式会社(旧三共株式会社)に入社。バイオロジクス創薬に従事後、知財部にて特許出願業務、特許戦略業務に従事。
得意分野はX線結晶構造解析、特許戦略。

Founder/Representative Director

Completed Graduate School of Engineering, University of Tokyo (Doctor of Engineering), University of Wales MBA Program (Master of Business Administration)

Joined Daiichi Sankyo Co., Ltd. (formerly Sankyo Co., Ltd.) in 1999. Engaged in research and development of biologics and cell therapy drugs at the Research Management Department.

His areas of expertise are antibody engineering, physical property analysis, and open innovation.

Director, Chief Technology Officer

Completed the Graduate School of Science, Nagoya University (Master of Science. Scheduled to obtain Doctor of Medicine in 2025)

Joined Kyowa Kirin in 2007 and Japan Tissue Engineering Co., Ltd. (J-TEC) in 2015.

Joined Daiichi Sankyo Co., Ltd. in 2020.
Engaged in research on cell therapy drugs at the Research Management Department.
His areas of expertise are hematology/tumor immunology, quality evaluation of regenerative medicine products, and process development.

Director, Chief Strategy Officer
Intellectual Property Officer

Completed Graduate School of Science, University of Tokyo (Doctor of Science), Globiz Graduate School of Management (Master of Business Administration)

Joined Daiichi Sankyo Co., Ltd. (formerly Sankyo Co., Ltd.) in 2002.
After working in biologics drug discovery, engaged in patent application work and patent strategy work at the Intellectual Property Department.

His areas of expertise are X-ray crystal structure analysis and patent strategy.